A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma

Journal of Pharmacological and Toxicological Methods

Volumn 53, Issue 3, 2006, Pages 284-290

  Skaggs, Sara M ^a   Foti, Robert S ^a   Fisher, Michael B ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Clearance; Hepatic metabolism; Liver microsomes; Protein binding; Scaling

Indexed keywords

AMITRIPTYLINE; DEXAMETHASONE; DICLOFENAC; KETAMINE; METOPROLOL; MIDAZOLAM; VERAPAMIL;

ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; EXPERIMENTATION; HUMAN; HUMAN CELL; LIVER CLEARANCE; LIVER METABOLISM; LIVER MICROSOME; MATHEMATICAL ANALYSIS; MEASUREMENT; PLASMA; PREDICTION; PROTEIN BINDING; QUALITY CONTROL;

ADRENERGIC BETA-ANTAGONISTS; AMITRIPTYLINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PROTEINS; CALCIUM CHANNEL BLOCKERS; DEXAMETHASONE; DICLOFENAC; EVALUATION STUDIES; HUMANS; KETAMINE; LIVER; MAGNESIUM CHLORIDE; METABOLIC CLEARANCE RATE; METOPROLOL; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NADP; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHOSPHATES; POTASSIUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; VERAPAMIL;

EID: 33646488018     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2005.10.002     Document Type: Article

References (26)

1. Austin R.P., Barton P., Cockroft S.L., Wenlock M.C., and Riley R.J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metabolism and Disposition 30 (2002) 1497-1503
2. Blanchard N., Richert L., Notter B., Delobel F., David P., Coassolo P., et al. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. European Journal of Pharmaceutical Sciences 23 (2004) 189-199
3. Eddershaw P.J., and Dickins M. Advances in in vitro drug metabolism screening. Pharmaceutical Sciences and Technology Today 2 (1999) 13-19
4. Foti R.S., and Fisher M.B. Impact of incubation conditions on bufuralol human clearance predictions: Enzyme lability and nonspecific binding. Drug Metabolism and Disposition 32 (2004) 295-304
5. Ghahramani P., Ellis S.W., Lennard M.S., Ramsay L.E., and Tucker G.T. Cytochrome P450 mediating N-demethylation of amitriptyline. British Journal of Clinical Pharmacology 43 (1997) 137-144
6. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology 47 (1994) 1469-1479
7. Houston J.B., and Carlile D.J. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metabolism Reviews 29 (1997) 891-922
8. Ito K., and Houston J.B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmaceutical Research 22 (2005) 103-112
9. Iwatsubo T., Hirota N., Ooie T., Suzuki H., Shimada N., Chiba K., et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics 73 (1997) 147-171
10. Kalvass J.C., Tess D.A., Giragossian C., Linhares M.C., and Maurer T.S. Influence of microsomal concentration on apparent intrinsic clearance: Implications for scaling in vitro data. Drug Metabolism and Disposition 29 (2001) 1332-1336
11. Lave T., Dupin S., Schmitt C., Chou R.C., Jaeck D., and Coassolo. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. Journal of Pharmaceutical Sciences 86 (1997) 584-590
12. Lin J.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metabolism and Disposition 26 (1998) 1202-1212
13. Ludden L.K., Ludden T.M., Collins J.M., Pentikis H.S., and Strong J.M. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: Implications for clinical correlation. Journal of Pharmacology and Experimental Therapeutics 282 (1997) 391-396
14. Mahmood I. Integration of in vitro data and brain weight in allometric scaling to predict clearance in humans: Some suggestions. Journal of Pharmaceutical Sciences 87 (1998) 527-529
15. Margolis J.M., and Obach R.S. Impact of nonspecific binding to microsomes and phospholipids on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metabolism and Disposition 31 (2003) 606-611
16. Masuda M., Kishimoto D., and Kurihara N. Rate parameter changes by added albumin in the microsomal oxidative demethylation of deuterated and non-deuterated 4-methoxyanisole. Biosciences, Biotechnology, and Biochemistry 60 (1996) 806-810
17. Obach R.S. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metabolism and Disposition 25 (1997) 1359-1369
18. Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones B.C., MacIntyre F., et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics 283 (1997) 46-58
19. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 27 (1999) 1350-1359
20. Pang K.S., and Rowland M. Hepatic clearance of drugs. 1. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Biopharmaceutics 5 (1977) 625-653
21. Rane A., Wilkinson G.R., and Shand D.G. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapeutics 200 (1977) 420-424
22. Rodrigues A.D. Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharmaceutical Research 14 (1997) 1504-1510
23. Shibata Y., Takahashi H., Chiba M., and Ishii Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metabolism and Disposition 30 (2002) 892-896
24. Tang C., Lin Y., Rodrigues A.D., and Lin J.H. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: An impact more than protein binding. Drug Metabolism and Disposition 30 (2002) 648-654
25. Venkatakrishnan K., Schmider J., Harmatz J.S., Ehrenberg B.L., von Moltke L.L., Graf J.A., et al. Relative Contribution of CYP3A to amitriptyline clearance in humans: In vitro and in vivo studies. Journal of Clinical Pharmacology 41 (2001) 1043-1054
26. Zhou Q., Matsumoto S., Ding L.R., Fischer N.E., and Inaba T. The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sciences 75 (2004) 2145-2155